Subscribe to our newsletter for industry insights and research updates.
Loading...
Influenza A/Victoria/4897/2022 (H1N1)pdm09-like Virus
Influenza A/Victoria/4897/2022 (H1N1)pdm09-like Virus is backordered and will ship as soon as it is back in stock.
To support our goal of supplying experiment-ready volumes of virus to our customers, we offer volume-based pricing. Adjusted pricing is applied during checkout.
- Purchase of one vial - list price
- Purchase of two vials - 10% off order
- Purchase of three vials - 20% off order
- Purchase of four or more vials - 30% off order
- For large orders, contact us for a custom quote.
- Academic customers - 60% off order.
Couldn't load pickup availability
Description: This virus is a reassortant influenza virus containing the HA and NA proteins from the influenza A/Victoria/4897/2022 (H1N1)pdm09 strain and all other genetic components from the master donor virus strain A/Puerto Rico/8/1934. It is a candidate virus for the H1N1 component of the trivalent egg-based influenza vaccine for the 2025-2026 northern hemisphere flu season.
Strain History: Influenza A/Victoria/4897/2022 (H1N1)pdm09 was identified from a human case in Victoria, Australia in 2022. The genomic sequence is available in the GISAID EpiFlu database under accession number EPI_ISL_16714268. Influenza A/Puerto Rico/8/1934 (H1N1) was isolated from a human in Puerto Rico in 1934. The genomic sequence is available by segment in NCBI (Segment 1/PB2; Segment 2/PB1; Segment 3/PA; Segment 4/HA; Segment 5/NP; Segment 6/NA; Segment 7/M2, M1; Segment 8/NEP, NS1).
Production:Plasmid-based reverse genetics method.
Biosafety Level: 2
Format: 1.0 mL/vial. Clarified and filtered cell culture supernatant frozen at -80°C. Delivered on dry ice.
QA/QC:
Shipping: As this product is an influenza-A virus strain, customers must submit a USDA APHIS permit VS 16-3 to Advanced Virology prior to order shipment. The permit and additional information are available at USDA APHIS Permits.
Production Batch Information links (downloadable):
Certificate of Analysis
NGS Results and Complete Genome Sequence
Batch Record: Detailed Production and QC Data
Product Use Policy and Material Transfer Agreement
Additional Formats: This product can be made as a purified or inactivated virus stock, or as purified viral genomic material. Many different reporter proteins and molecular tags can also be incorporated. Custom variant design and production services are also available. Please contact us for additional information.
Additional Strains: If you require a strain of this virus not listed on our website, please contact us. We can produce a wide range of common strains to meet your needs.
Additional Viruses Available: If you are looking for a virus species or strain not listed on our website, please contact us with your request. Our team will work with you to create the product that meets your research needs and budget.
Strain History: Influenza A/Victoria/4897/2022 (H1N1)pdm09 was identified from a human case in Victoria, Australia in 2022. The genomic sequence is available in the GISAID EpiFlu database under accession number EPI_ISL_16714268. Influenza A/Puerto Rico/8/1934 (H1N1) was isolated from a human in Puerto Rico in 1934. The genomic sequence is available by segment in NCBI (Segment 1/PB2; Segment 2/PB1; Segment 3/PA; Segment 4/HA; Segment 5/NP; Segment 6/NA; Segment 7/M2, M1; Segment 8/NEP, NS1).
Production:Plasmid-based reverse genetics method.
Biosafety Level: 2
Format: 1.0 mL/vial. Clarified and filtered cell culture supernatant frozen at -80°C. Delivered on dry ice.
QA/QC:
- Infectious titer
- Genome equivalents/mL by qPCR
- Whole-genome sequencing by NGS
- Mycoplasma test by PCR
- Sterility test for bacterial and fungal contamination
- Endotoxin test <10 EU/mL
- Documentation: Experimental conditions for QC tests, documentation of all reagents used.
Shipping: As this product is an influenza-A virus strain, customers must submit a USDA APHIS permit VS 16-3 to Advanced Virology prior to order shipment. The permit and additional information are available at USDA APHIS Permits.
Production Batch Information links (downloadable):
Certificate of Analysis
NGS Results and Complete Genome Sequence
Batch Record: Detailed Production and QC Data
Product Use Policy and Material Transfer Agreement
Additional Formats: This product can be made as a purified or inactivated virus stock, or as purified viral genomic material. Many different reporter proteins and molecular tags can also be incorporated. Custom variant design and production services are also available. Please contact us for additional information.
Additional Strains: If you require a strain of this virus not listed on our website, please contact us. We can produce a wide range of common strains to meet your needs.
Additional Viruses Available: If you are looking for a virus species or strain not listed on our website, please contact us with your request. Our team will work with you to create the product that meets your research needs and budget.